Global Bioprinting on Organ Transplant Market - 2024-2031

Report Overview

The Global Bioprinting on Organ Transplant Market reached US$ 1.05 billion in 2023 and is expected to reach US$ 2.73 billion by 2031, growing at a CAGR of 13.2% during the forecast period 2024-2031.

Biomanufacturing of organs/tissues in vitro has been driven by two needs, i.e., organ transplantation and accurate tissue models. Bioprinting, also known as three-dimensional (3D) printing, is a technique used to develop many tissues/organs, such as the liver, skin, and heart. This technique is associated with printing structures using biomaterials, viable cells, and biomolecules. The creation of bioartificial organs has opened new avenues for future organ transplantation programs.

The demand for organ transplants has increased rapidly worldwide. Organ transplants are required due to the increased incidence of vital organ failure and the higher success rate of post-transplant outcomes. Globally, a major organ shortage crisis has emerged due to higher demand and insufficient supply of organs for transplant. 3D bioprinting uses cells or other bio-materials as printing inks to print complex 3D biological structures with biological functions according to the requirements of the bionic morphology, biological function, and cellular microenvironment through additive manufacturing methods.

Market Dynamics: Drivers

Increasing need for organ transplantation

The demand for global bioprinting on organ transplantation market is driven by multiple factors. The increase in the need for artificial organs and organ transplantation propels the market growth.

Furthermore, the demand for global bioprinting on organ transplantation market will be fueled by technological developments and funding allotted for research work. For instance, according to transplant.hrsa.gov, There were 46,632 organ transplants performed from both living and deceased donors in 2023. This represents an 8.7 percent increase over 2022 and a 12.7 percent increase over 2021, which was the first year with more than 40,000 organ transplants. There were 39,679 organ transplants from deceased donors. This represents an 8.9 percent increase over 2022 and marks the eleventh consecutive record-setting year.

For instance, according to an article posted by nih.gov in February 2024, India sees 17,000-18,000 solid organ transplants performed every year, the most in the world after the US and China, but remains behind several high-income countries in transplantation rates per million population (0.65). There has been progress in this area, such as an improvement in the harvesting of organs from deceased donors, with the average number of organ transplants per donor increasing from 2.43 in 2016 to 3.05 in 2022.

Restraints

Factors such as side effects and risks related to organ transplantation, the high cost of artificial organs, the shortage of skilled professionals, and stringent regulatory requirements for the approval of new techniques are expected to hamper the market.

Market Segment Analysis

The global bioprinting on organ transplantation market is segmented based on process, bioink, cell type used, end-user, and region.

The segment extrusion-based bioprinting accounted for approximately 47.8% of the global bioprinting on organ transplantation market share

The extrusion-based bioprinting segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research work would drive this market.

Extrusion-based bioprinting is a powerful three-dimensional (3D) bioprinting technology that provides unique opportunities for use in organ fabrication. This technology has grown rapidly during the last decade. Extrusion-based bioprinting provides great versatility in printing various biological compounds or devices, including cells, tissues, organoids, and microfluidic devices that can be applied in basic research, pharmaceutics, drug testing, transplantation, and clinical uses. Extrusion-based bioprinting offers great flexibility in printing a wide range of bioinks, including tissue spheroids, cell pellets, microcarriers, decellularized matrix components, and cell-laden hydrogels.

For instance, in April 2022, Finland-based bioprinting startup Brinter announced the launch of a new extrusion-based Visco Bio medical printhead for its bioprinters. New modular printheads introduced in close collaboration with Puredyne, who provides innovative technologies to the market, allow waste of expensive medical grade materials to be kept to a minimum.

Market Geographical Share

North America accounted for approximately 42.5% of the global bioprinting on organ transplantation market share

North America region is expected to hold the largest market share over the forecast period. The increasing demand for organ transplantation, and technological advancements, in this region, help to propel the market.

For instance, according to an article published by hrsa.gov, in January 2024, More than 16,000 deceased organ donors, a new annual record and a continuation of a 13-year annual record trend. More than 46,000 organ transplants were performed, continuing an annual record-setting trend. More than 10,000 transplant recipients were Black, and non-Hispanic. More than 10,000 liver transplants were performed for the first time. More than 3,000 lung transplants were performed for the first time. New annual records are also set for kidney and heart transplants.

For instance, in November 2023, Cellink and Ossiform entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform's existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through Cellink's commercial channels. Cellink and Ossiform are planning to capitalize on synergies and bring to the market a highly functional bio-ink for bone-based research. The partnership has scope for additional materials, including clinical-grade bioinks.

Market Segmentation

By Process

• Inkjet Bioprinting
• Laser-Assisted Bioprinting
• Extrusion-Based Bioprinting
• Acoustic Bioprinting
• Magnetic Bioprinting
• Vatphotopolymerization-based bioprinting
• Others

By Bioink

• PEG diacrylate
• Nanocellulose
• Collagen I
• Graphene
• Others

By Cell Type Used

• iPS Cells
• Mesenchymal Stem Cells
• Keratinocytes
• Neural Stem Cell
• Others

By End-User

• Hospitals
• Research and Educational Institutions
• Specialty Clinics
• Organ Transplantation Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the global bioprinting on organ transplantation market include 3D Systems Corporation, Protolabs, Materialise, Stratasys, General Electric Company, Desktop Metal Inc., Aspect Biosystems Ltd., EnvisionTEC Llc., Ibio Inc., and Printivo among others.

Key Developments

• In September 2022, 3D Systems announced the formation of a new, wholly-owned company called Systemic Bio(TM), a biotech company focused on the application of advanced bioprinting technologies to pharmaceutical drug discovery and development. Systemic Bio will leverage 3D Systems' breakthrough, production-level bioprinting technology to create extremely precise vascularized organ models using biomaterials and human cells.
• In October 2023, Carcinotech and 3D bioprinting firm CELLINK announced a partnership to accelerate cancer drug development with 3D bio-printed tumor models. The partnership will focus on the development and commercialization of cutting-edge protocols for the biofabrication of 3D bio-printed tumor models using cancer cell lines. These models are designed to significantly improve accuracy and speed up drug development processes, ultimately reducing development costs and enhancing research output. The protocols will be made available for use on CELLINK's state-of-the-art BIO CELLX system.
• In June 2022, CollPlant a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the initiation of a study in large animals for its 3D bioprinted regenerative breast implant program, addressing the $2.8 billion global breast implant market.

Why Purchase the Report?

To visualize the global bioprinting on organ transplantation market segmentation based on, process, bioink, cell type used, end-user, and region, as well as understand key commercial assets and players.

• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global bioprinting on organ transplantation market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global bioprinting on organ transplantation market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies